Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$32 Mln
Revenue (TTM)
$-4 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.7
Industry P/E
--
EV/EBITDA
1.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-24.1
Face value
--
Shares outstanding
1,261,685
CFO
$-137.90 Mln
EBITDA
$-164.34 Mln
Net Profit
$-173.04 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sensei Biotherapeutics (SNSE)
| 226.1 | 14.1 | 226.1 | 341.5 | 5.1 | -34.6 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Sensei Biotherapeutics (SNSE)
| 8.9 | -29.0 | -53.6 | -74.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sensei Biotherapeutics (SNSE)
|
34.8 | 31.7 | -4.3 | -24.1 | 559.4 | -87.8 | -- | 1.7 |
| 62.9 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.6 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.0 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.2 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.1 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.8 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 489.5 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 319.3 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly... selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. Address: 1405 Research Boulevard, Rockville, MD, United States, 20850 Read more
President, CEO & Director
Mr. John K. Celebi M.B.A.
President, CEO & Director
Mr. John K. Celebi M.B.A.
Headquarters
Rockville, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Sensei Biotherapeutics Inc (SNSE) is $34.79 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Sensei Biotherapeutics Inc (SNSE) has given a return of 5.06% in the last 3 years.
Since, TTM earnings of Sensei Biotherapeutics Inc (SNSE) is negative, P/E ratio is not available.
The P/B ratio of Sensei Biotherapeutics Inc (SNSE) is 1.73 times as on 31-Mar-2026, a 56 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.02
|
0.01
|
|
2023
|
-0.02
|
0.01
|
|
2022
|
-0.06
|
0.03
|
|
2021
|
-0.16
|
0.04
|
|
2020
|
--
|
--
|
The 52-week high and low of Sensei Biotherapeutics Inc (SNSE) are Rs 36.76 and Rs 5.21 as of 02-Apr-2026.
Sensei Biotherapeutics Inc (SNSE) has a market capitalisation of $ 32 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sensei Biotherapeutics Inc (SNSE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$3.27
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.